Research Report University Hospital clinical trial EC-FV-06

Abstract

A randomized, double-blind Phase 3 study to compare the product ECI45 in combination with pegylated liposomal doxorubicin (PLD / Doxil (R) / Caelyx (R)) versus PLD in patients with ovarian cancer resistant to platinum

Keywords

• ovarian cancer
• pegylated liposomal doxorubicin